Karakiewicz Pierre I, Trinh Quoc-Dien, Rioux-Leclercq Nathalie, de la Taille Alexandre, Novara Giacomo, Tostain Jacques, Cindolo Luca, Ficarra Vincenzo, Artibani Walter, Schips Luigi, Zigeuner Richard, Mulders Peter F, Lechevallier Eric, Coulange Christian, Valeri Antoine, Descotes Jean-Luc, Rambeaud Jean-Jacques, Abbou Claude C, Lang Herve, Jacqmin Didier, Mejean Arnaud, Patard Jean-Jacques
Cancer Prognostics and Health Outcome Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Eur Urol. 2007 Oct;52(4):1140-5. doi: 10.1016/j.eururo.2007.01.070. Epub 2007 Jan 31.
Collecting duct renal cell carcinoma (CDRCC) is a rare but reportedly aggressive histologic subtype. We assessed the stage and histologic features of patients with CDRCC and compared cancer-specific mortality in CDRCC and matched patients with clear-cell renal cell carcinoma (CRCC).
Forty-one (0.6%) patients with CDRCC and 5246 CRCC patients were identified within a cohort of 6608 patients treated with either radical or partial nephrectomy for renal cancer. Within the 5246 CRCC cases, 105 were matched with CDRCC cases for grade, tumour size, and T, N, and M stages. Kaplan-Meier and life table analyses addressed RCC-specific survival.
Of all CDRCC patients, 76% had pT3 disease at nephrectomy versus 37% for those with CRCC. The predominant Fuhrman grades were III (56%) and IV (22%) in CDRCC versus II (42%) and III (28%) for CRCC. Moreover, 49% of CDRCC patients were pN1-2 versus 8% for CRCC. Of CDRCC patients 19% had distant metastases at nephrectomy versus 14% for CRCC. Finally, 73% of CDRCC patients had either local or systemic symptoms versus 56% for CRCC. After matching, the RCC-specific mortality of CDRCC patients was no different from that for CRCC patients (RR=1.1; p=0.8). One- and 5-yr CDRCC-specific survival rates were 86% and 48%, respectively, versus 86% and 57% for matched CRCC controls.
CDRCC patients present with more advanced stage and with more aggressive disease compared with CRCC patients. After nephrectomy, when CDRCC cases were matched with CRCC, the same cause-specific survival was seen.
集合管肾细胞癌(CDRCC)是一种罕见但据报道具有侵袭性的组织学亚型。我们评估了CDRCC患者的分期和组织学特征,并比较了CDRCC患者与匹配的透明细胞肾细胞癌(CRCC)患者的癌症特异性死亡率。
在6608例接受肾癌根治性或部分肾切除术的患者队列中,确定了41例(0.6%)CDRCC患者和5246例CRCC患者。在5246例CRCC病例中,105例与CDRCC病例在分级、肿瘤大小以及T、N和M分期方面进行了匹配。采用Kaplan-Meier法和生命表分析法评估肾癌特异性生存率。
在所有CDRCC患者中,76%在肾切除时为pT3期,而CRCC患者为37%。CDRCC中主要的Fuhrman分级为III级(56%)和IV级(22%),而CRCC中为II级(42%)和III级(28%)。此外,49%的CDRCC患者为pN1-2期,而CRCC患者为8%。CDRCC患者中有19%在肾切除时发生远处转移,而CRCC患者为14%。最后,73%的CDRCC患者有局部或全身症状,而CRCC患者为56%。匹配后,CDRCC患者的肾癌特异性死亡率与CRCC患者无差异(RR = 1.1;p = 0.8)。CDRCC患者1年和5年的肾癌特异性生存率分别为86%和48%,而匹配的CRCC对照组为86%和57%。
与CRCC患者相比,CDRCC患者表现为更晚期和更具侵袭性的疾病。肾切除术后,当CDRCC病例与CRCC匹配时,观察到相同的病因特异性生存率。